-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $76

Benzinga·07/16/2026 20:19:14
语音播报
Citigroup analyst Eric Joseph maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $75 to $76.